BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa
Stockholm, Sweden, September 24, 2026 – BOOST Pharma (“BOOST” or “the Company”), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced that it has been selected as a 2026 Innovation Spotlight company at the upcoming Cell & Gene Meeting on the Mesa, taking place in Phoenix, Arizona, US, from 5-7 October 2026.
